FIELD: medicine, oncology. SUBSTANCE: malignant cells are removed from patient, ruptured their and proteins of the main complex of histocompatibility of the first and the second type are separated. Then these proteins are administrated in the region of malignant formation to the same patient. Method ensures to switch on mechanism of immune system (T-cells) for malignant cells killing. EFFECT: improved method of treatment. 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOMODULATING SELENIUM-CONTAINING PHOSPHOLIPOGLYCOPROTEIN ORGANOELEMENTAL AGENT AND METHOD OF IMMUNOMODULATION | 2000 |
|
RU2167652C1 |
| METHOD OF TREATING CANCER | 2009 |
|
RU2429019C2 |
| METHOD FOR GENERATION OF HIGH-ENERGY PHONONS IN LATTICE STRUCTURES | 1994 |
|
RU2107978C1 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| TOLL-LIKE RECEPTOR 7 OR 8 AGONIST AND CHOLESTEROL COMPLEX AND ITS USE | 2020 |
|
RU2790702C1 |
| METHODS FOR PREDICTION OF APPLICABILITY OF PROTEINS OR PROTEIN FRAGMENTS FOR IMMUNOTHERAPY | 2017 |
|
RU2782336C2 |
| IMMUNOTHERAPY METHOD FOR TREATING PATIENTS FOR SOLID TUMORS BY APPLYING TUMOR LYSATE WITH BETALEUKINE ADJUVANT | 2004 |
|
RU2267326C2 |
| SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMELIZED SINGLE-CHAIN ANTIBODIES, AIMED TO ONCOTIC RECEPTORS CD47/ERBB2, INTENDED FOR THE THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2648164C1 |
| TUMOUR-REJECTING GLYPICAN-3 (GPC3)-DERIVATIVE ANTIGENIC PEPTIDES USED FOR HLA-A2-POSITIVE PATIENTS, AND PHARMACEUTICAL PRODUCT CONTAINING SAID PEPTIDES | 2006 |
|
RU2395519C2 |
| SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMEL SINGLE-CHAIN ANTIBODIES, AIMED ON TUMOR RECEPTORS CD47/CD44, INTENDED FOR THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2658764C1 |
